低剂量米非司酮治疗子宫肌瘤的疗效观察

Observation on the therapeutic effect of low dose mifepristone in the treatment of uterine fibroids

目的探讨低剂量米非司酮治疗子宫肌瘤的疗效及安全性。方法将2012—03—2013—10湖北省武汉市江夏区人民医院收治的85例子宫肌瘤患者分为两组，观察组43例患者，口服米非司酮（12．5mg／d）进行治疗；对照组42例患者，口服米非司酮（25mg／d）进行治疗，坚持用药3个月。3个月后B超测量患者子宫肌瘤的径线（体积），并随访6个月，观察比较两组的治疗效果、安全性。结果治疗3个月后，观察组肌瘤缩小与对照组相比，差异无统计学意义，P〉0．05；血红蛋白含量显著上升、痛经症状显著改善，P〈O．05；潮热出汗率等并发症发生率远低于对照组，差异有统计学意义，P〈O．05，两组患者的行经期均有显著改善，但差异无统计学意义，P〉0．05。结论两种剂量米非司酮治疗子宫肌瘤均能取得良好的疗效，但是低剂量（12．5mg／d）的给药方式更安全、有效。

OBJECTIVE To investigate the curative effect of low-dose mifepristone treatment of uterine fibroids, and safety. METHODS In March 2012 to October 2013 in our hospital treated 85 cases of hysteromyoma patients were randomly divided into two groups, 43 patients of observation group oral mifepristone treatment （12.5 rag/d）, 42 patients as control group oral mifepristone （25 rag/d） treatment, adhere to the medication for 3 months. 3 months with ultrasound measurement in patients with uterine fibroids lines （volume）, and were followed up for 6 months, compare two groups of therapeutic effect and safety. RESULTS Three months after treatment to observe group fibroids narrowing there was no significant difference compared with control group （P〈0. 05）. Hemoglobin levels rise sharply, symptoms improved sig- nificantly （P〈0.05）, the incidence of complications such as hot flashes sweating rate is far lower than the control group （P〈0.05）, the difference is statistically significant. Menstruation period were improved significantly in both groups （P〉0. 05）, no statistically significant difference. CONCLUSION Two doses of mifepristone treatment of uterine fibroids can achieve good curative effect, but low dose （12.5 mg/d） is safer and more effective ways of drug delivery.